Neurogene locks in 25-patient analysis for Rett gene therapy as cash stretches to 2029

Neurogene has told investors it has enough money to run into the first quarter of 2029, a horizon that extends past the expected readout of its pivotal Rett syndrome gene therapy study. The company reported cash of $359.7m with its third-quarter results on 9 November 2026.

The pivotal study, called Embolden, tests NGN-401, an investigational AAV9-based gene therapy. Topline results are now guided to the second half of 2027. Neurogene said the main analysis will include all 25 participants who received the therapy, and that it settled this approach with the US Food and Drug Administration through the agency's START pilot. The trial will be judged a success if at least 9 of those 25 patients are responders.

On manufacturing, Neurogene said process performance qualification runs for the planned biologics licence application are on track to finish by the end of 2026. This is the step in which a producer shows that its commercial-scale process repeatedly yields product of the required quality. The company gave no further detail on the runs.

The company also gave an update on safety. Neurogene said that at the 1E15 vg dose, data from 35 patients show tolerability that remains broadly good. It did not provide further breakdowns in the update.